These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

904 related items for PubMed ID: 19516174

  • 1. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.
    Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, Thomopoulos C, Syrseloudis D, Stefanadi E, Mihas C, Katsi V, Papademetriou V, Stefanadis C.
    J Hypertens; 2009 Apr; 27(4):744-52. PubMed ID: 19516174
    [Abstract] [Full Text] [Related]

  • 2. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M, Noberasco G, Re M, Filippi A, Gallina AM, Weiss U, Cannavò R, Ravera G, Cricelli C, Deferrari G.
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [Abstract] [Full Text] [Related]

  • 3. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.
    Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.
    J Hypertens Suppl; 1996 Dec; 14(5):S43-9. PubMed ID: 9120684
    [Abstract] [Full Text] [Related]

  • 4. [Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney].
    Tomilina NA, Storozhakov GI, Gendlin GE, Badaeva SV, Zhidkova DA, Kim IG, Borisovskaia SV, Loss KE, Fedorova ND.
    Ter Arkh; 2007 Dec; 79(6):34-40. PubMed ID: 17684964
    [Abstract] [Full Text] [Related]

  • 5. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

  • 6. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial.
    Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K, CASE-J trial Group.
    Hypertens Res; 2009 Apr 28; 32(4):248-54. PubMed ID: 19347033
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 8. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM, LIFE Study Investigators.
    J Hypertens; 2006 Apr 14; 24(4):775-81. PubMed ID: 16531808
    [Abstract] [Full Text] [Related]

  • 9. [Left ventricular hypertrophy among hypertensive patients with diminished glomerular filtration rate].
    Grabysa R, Cholewa M.
    Pol Merkur Lekarski; 2008 Oct 14; 25(148):309-14. PubMed ID: 19145927
    [Abstract] [Full Text] [Related]

  • 10. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B.
    Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333
    [Abstract] [Full Text] [Related]

  • 11. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Sep 01; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

  • 12. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB.
    J Hum Hypertens; 2007 Aug 01; 21(8):625-32. PubMed ID: 17476291
    [Abstract] [Full Text] [Related]

  • 13. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease.
    Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ.
    J Am Soc Nephrol; 2005 Jun 01; 16(6):1803-10. PubMed ID: 15857925
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The combination of chronic kidney disease and increased arterial stiffness is a predictor for stroke and cardiovascular disease in hypertensive patients.
    Ohishi M, Tatara Y, Ito N, Takeya Y, Onishi M, Maekawa Y, Kato N, Kamide K, Rakugi H.
    Hypertens Res; 2011 Nov 01; 34(11):1209-15. PubMed ID: 21814210
    [Abstract] [Full Text] [Related]

  • 17. [Association between hypertensive left ventricular hypertrophy and cardiovascular events in adult Beijing residents: a cohort study].
    Li Y, Zhao D, Liu J, Li CF, Guo W, Chen CH, Hao P, Sun JY, Qin LP, Wang W.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Nov 01; 36(11):1037-42. PubMed ID: 19102921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):705-11. PubMed ID: 15734614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.